Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Retrospective, Multicenter, Single-arm Real-world Study on a New Adjuvant Chemotherapy Combined With Immune Inhibitors for Resectable Esophageal Squamous Cell Carcinoma (ESCC)

NCT06472635 is registered in ClinicalTrials.gov with Zhejiang University as lead sponsor.

NCT NCT06472635
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06472635 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Retrospective, Multicenter, Single-arm Real-world Study on a New Adjuvant Chemotherapy Combined With Immune Inhibitors for Resectable Esophageal Squamous Cell Carcinoma (ESCC)
Lead sponsor
Zhejiang University
Phase
Observational
Overall status
Unknown status
Start date
March 1, 2022
Completion date
October 31, 2024
Enrollment
95 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

the neoadjuvant treatment for resectable esophageal squamous cell carcinoma